US2016185877A1PendingUtilityA1
Lox and loxl2 inhibitors and uses thereof
Est. expiryAug 2, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Victoria SmithScott OggPeter Van VlasselaerVivian E. BarryDerek MarshallAlison Kay HolzerHector RodriguezMiho OyasuScott Alan MccauleyCarlos Aurelio GarciaDonna Hiroko Tokuoka Biermann
A61P 9/12A61P 9/00A61P 9/10A61P 35/04A61P 43/00A61P 3/10A61P 25/00A61P 25/28A61P 35/00A61P 11/00A61P 13/08A61P 13/12A61P 13/10A61P 1/16A61P 15/00A61P 1/04A61P 21/00A61P 17/00A61P 1/18A61P 17/02A61P 19/04A61P 19/00G01N 33/57525G01N 33/5758G01N 33/5752A61K 2039/505C07K 2317/33A61K 39/3955G01N 2333/90633C07K 2317/76C07K 2317/30C07K 2317/92C12Q 1/6886C07K 16/40C07K 2317/24C07K 2317/565C07K 2317/77A61K 45/06C07K 2317/34Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
Claims
exact text as granted — not AI-modified1 . An isolated antibody or antigen binding fragment thereof, that specifically binds to an epitope having an amino acid sequence set forth as SEQ ID NO: 6.
Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.